Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Blood
Patent
1996-07-25
1998-03-24
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Blood
424530, 424531, 424532, 424533, 424534, 514 40, A61K 3514, A61K 3516, A61K 3518
Patent
active
057310076
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to novel pharmaceutical composition for skin diseases, in particular which comprises deproteinized dialysate of calf's blood and aminoglycoside antibiotic as active ingredients.
BACKGROUND OF THE INVENTION
It is known that skin diseases, e.g. burns, wounds, general operative wounds, pernio, decubitus, folliculitis, impetigo, intertrigo, radiation ulcer, acne vulgaris or infectious eczematous dermatitis develop erythema, swelling, bulla, erosion, or ulcer etc., being accompanied with bacterial infections.
For the treatement of those skin diseases, tissue regeneration activators which can accelerate regeneration of the necrotinized tissue and 10,107-115 (1984)!. However, it has been pointed out as demerits that those activators are unable to prevent appropriately bacterial infections in foci during the treatment.
In addition, topical dosage forms containing antibiotics and being formulated with proper skin protecting bases have been developed for the 519-526(1985)!. Those formulations could partially achieve preventing bacterial infections in foci, but they could not achieve the most preferable treatments due to lack of the ability to accelerate regeneration of the necrotinized tissue and fibroblast proliferation.
SUMMARY OF THE INVENTION
The present inventors fixed eye on the possibility that if the two drugs with different mechanisms of action are combined to formulate a dosage form from which the dissolutions of the two ingredient are superior to those of the same ingredients from the conventional ointment or cream used for treatment of skin diseases, such as burns, having potential to be infected with bacteria, synergism of the two drugs can normalize skin function more effectively. Then the present inventors have carried out extensive research to develop a useful pharmaceutical composition which accelerate tissue regeneration and at the same time have antibacterial activity for treatment of skin diseases; and as a result, have discovered the excellent treatment of the diseases and decrease of the expression of acute skin diseases are obtained when deproteinized dialysate of calf's blood and aminoglycoside antibiotic were combined to treat skin diseases. The deproteinized dialysate of calf's blood has the ability to accelerate tissue regeneration, and the antibiotic has antimicrobial activity and the deproteinized dialysate of calf's blood in combination of antibiotic also compensates the demerits of each component.
Accordingly, it is an object of the present invention to provide novel pharmaceutical composition useful for treatment of skin diseases, which can give an immediate therapeutic effects through the well-marked tissue regenerative action and the effective antibacterial action, and shorten therapeutic period.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is to provide a novel pharmaceutical composition useful for treatment of skin diseases comprising deproteinized dialysate of calf's blood and aminoglycoside antibiotic as active ingredients.
Deproteinized dialysate of calf's blood, tissue regenerative component of the composition of the present invention, is protein-tree haemodialysate obtained by drawing the blood from the reticuloendothelial system of the fully grown young calf regenerated by the special organ extraction method and then removing protein completely through dialysis. The deproteinized dialysate of calf's blood is sold in the trademark of Solcoseryl.RTM. (Solco Basle Ltd., Swiss). It is known that the said deproteinized dialysate of calf's blood includes organic compounds, such as amino acid, ketonic acid, oxy acids, deoxy ribosides, purines, and unknown polypeptide, etc., and inorganic compounds, such as Na, K, Ca, Fe, Co, P, Chloride, and N, to increase utilization of oxygen in cells and to accelerate regeneration of the necrotinized tissue and formation of 750.about.754 (1965); VASA Band Vol. 2, 81.about.83 (1973)!.
Aminoglycoside antibiotic, bacterial infection inhibitory component of the s compositi
REFERENCES:
patent: 3293836 (1966-12-01), Heth
patent: 3932618 (1976-01-01), Fujii et al.
patent: 4177261 (1979-12-01), Dietze et al.
patent: 5290555 (1994-03-01), Guthauser et al.
Budarari et al. "The Merck Index" (11th Ed.), Merck and Co., Inc., Rahway, NJ. (1989), pp. 972-973.
Chang Man Sik
Choi Wahn Soo
Chun Jae Kwang
Chun Jong Ok
Chung Kae Jong
Cintins Marianne M.
Moezie M.
Yungjin Pharmaceutical Co., Ltd.
LandOfFree
Pharmaceutical composition for skin diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for skin diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for skin diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2286875